Synapse

← Safety and Risk of Pharmacotherapy

Papers in Safety and Risk of Pharmacotherapy

Page 2 · newest first

  1. Role of Pharmacogenetic Testing in the Risk and Safety Assessment of Valproates: The Ethnic Aspect (Review)Safety and Risk of Pharmacotherapy · 2024
  2. Patients’ Pharmacogenetic Characteristics and the Risk of Adverse Reactions to Non-steroidal Anti-inflammatory Drugs: Case ReportsSafety and Risk of Pharmacotherapy · 2024
  3. “Implementing the pharmacovigilance system and publishing this journal, we were helping healthcare providers cultivate the sense of professional and civic responsibility”Safety and Risk of Pharmacotherapy · 2024
  4. Current Information on the Safety of Medicinal Products: Decisions of Foreign Regulatory AuthoritiesSafety and Risk of Pharmacotherapy · 2024
  5. Adverse Events Following Vaccination: A Review of Russian and International TerminologySafety and Risk of Pharmacotherapy · 2024
  6. Magnesium Orotate Influence on Thoracic Aorta in Laboratory Rabbits Receiving LevofloxacinSafety and Risk of Pharmacotherapy · 2024
  7. Retrospective Analysis of Spontaneous Reports of Fatal Adverse Reactions Associated with LidocaineSafety and Risk of Pharmacotherapy · 2023
  8. In Silico Estimation of the Safety of Pharmacologically Active Substances Using Machine Learning Methods: A ReviewSafety and Risk of Pharmacotherapy · 2023
  9. In Silico Prediction of Toxicological and Pharmacokinetic Characteristics of Medicinal CompoundsSafety and Risk of Pharmacotherapy · 2023
  10. Pharmacogenetics-Informed Pharmacometabolomics as an Innovative Approach to Assessing the Safety and Risk of Pharmacotherapy with Valproic AcidSafety and Risk of Pharmacotherapy · 2023
  11. Digital Pharmacotherapy Support for Medication AdherenceSafety and Risk of Pharmacotherapy · 2023
  12. Clinical Pharmacology of Antimicrobials: Focus on the Safety of Vancomycin and LinezolidSafety and Risk of Pharmacotherapy · 2023
  13. PCSK9 Inhibitor Therapy as an Alternative for Statin IntoleranceSafety and Risk of Pharmacotherapy · 2023
  14. PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New MedicinesSHILAP Revista de lepidopterología · 2023
  15. Safety of Lipid-Lowering Therapy with Statins according to a Regional Pharmacovigilance CentreSafety and Risk of Pharmacotherapy · 2023
  16. Statin-Induced MyopathySafety and Risk of Pharmacotherapy · 2023
  17. Opportunities and Prospects for Preclinical Drug Safety Assessment Using Alternative Methods: Experience from the Toxicology in the 21st Century (Tox21) Programme in the USASafety and Risk of Pharmacotherapy · 2023
  18. Bempedoic Acid: Safety and Efficiacy of a New Lipid-Lowering AgentSafety and Risk of Pharmacotherapy · 2023
  19. Using Zebrafish in Preclinical Drug Studies: Challenges and OpportunitiesSafety and Risk of Pharmacotherapy · 2023
  20. Antimicrobial Resistance: A Risk Factor for the Biosafety SystemSafety and Risk of Pharmacotherapy · 2023
  21. Current Approaches to Assessing the Safety and Efficacy of Lamotrigine in Children and Adolescents with Epileptic Syndromes Associated with Focal SeizuresSafety and Risk of Pharmacotherapy · 2023
  22. Diabetes Mellitus after COVID-19 Vaccination in a Patient with Impaired Glucose Metabolism: Case ReportSafety and Risk of Pharmacotherapy · 2023
  23. Safety Study of an Original Mesenchymal Stromal Cell Secretome-Based Medicinal Product for Spermatogenesis RestorationSafety and Risk of Pharmacotherapy · 2023
  24. Comparative Preclinical Evaluation of the Safety, Antifungal Activity, and Pharmacokinetics of Sertaconazole Products for External UseSafety and Risk of Pharmacotherapy · 2023
  25. Idiosyncratic Drug-Induced Liver Injury: From Pathogenesis to Risk ReductionSafety and Risk of Pharmacotherapy · 2023
  26. Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)Safety and Risk of Pharmacotherapy · 2023
  27. Clinical Signs and Medical History as Predictors of Enalapril-Associated Dry Cough in Cardiovascular PatientsSafety and Risk of Pharmacotherapy · 2023
  28. Susceptibility of HEK293 and RPTEC Cell Lines to Nephrotoxic Effects of Cefuroxime and Cefepime: A Comparative StudySafety and Risk of Pharmacotherapy · 2023
  29. In Vitro Assessment of Drug-Induced Liver Injury Using Cell-Based Models: A ReviewSafety and Risk of Pharmacotherapy · 2023
  30. Off-Label Prescribing in Paediatric Cardiology: Regulatory Aspects and Safety Assessment by Spontaneous ReportingSafety and Risk of Pharmacotherapy · 2023
  31. Retrospective Analysis of the Safety of Antibacterial Medicinal Products for Elderly Patients with Community-Acquired Lower Respiratory Tract InfectionsSafety and Risk of Pharmacotherapy · 2023
  32. Gene Therapy Medicinal Products: Non-clinical Safety StudiesSafety and Risk of Pharmacotherapy · 2023
  33. Structure of Adverse Events Following Immunisation against Coronavirus Infection (COVID-19) in the Kyrgyz RepublicSafety and Risk of Pharmacotherapy · 2022
  34. Methodological Approaches to Studying Fatal Adverse Drug ReactionsSafety and Risk of Pharmacotherapy · 2022
  35. Sodium Metamizole: Regulatory Status around the World, Safety Problems and Medication ErrorsSafety and Risk of Pharmacotherapy · 2022
  36. Safety of Pharmacotherapy in COVID-19 Patients: A Literature ReviewSafety and Risk of Pharmacotherapy · 2022
  37. Pharmacokinetic Interactions of Phenosanic Acid with Valproic Acid and Carbamazepine in DogsSafety and Risk of Pharmacotherapy · 2022
  38. Single-Dose Bioequivalence Study of Rivaroxaban-Containing Medicinal Products in Healthy VolunteersSafety and Risk of Pharmacotherapy · 2022
  39. Approaches to Assessing the Safety of Medicines during the COVID-19 Pandemic Using the Example of AzithromycinSafety and Risk of Pharmacotherapy · 2022
  40. New Technologies in Electronic Pharmacovigilance Systems for Marketing Authorisation HoldersSafety and Risk of Pharmacotherapy · 2022
  41. Assessment of Safety Signals for Aztreonam in Different Age Groups: National and International Drug Safety MonitoringSafety and Risk of Pharmacotherapy · 2022
  42. Therapeutic Drug Monitoring for Evaluation of the Efficacy and Safety of Vancomycin in Patients with Orthopaedic InfectionsSafety and Risk of Pharmacotherapy · 2022
  43. Efficacy and Safety of Ascites Treatment in Liver CirrhosisSafety and Risk of Pharmacotherapy · 2022
  44. Experimental Study of the Efficacy and Safety of a New PEG-Based LaxativeSafety and Risk of Pharmacotherapy · 2022
  45. Evaluation of the Effect of Comorbidity on the Efficacy and Safety of β-Lactam Antibiotics in Patients with Community-Acquired PneumoniaSafety and Risk of Pharmacotherapy · 2022
  46. Experience of Using Therapeutic Drug Monitoring to Control the Safety of Vancomycin in Intensive Care Unit Patients with SepsisSafety and Risk of Pharmacotherapy · 2022
  47. Automated Information Systems as a New Approach to Risk Management of Pharmacotherapy in the Treatment of EpilepsySafety and Risk of Pharmacotherapy · 2022
  48. Ivermectin: Evaluation of Efficacy and Safety in COVID-19Safety and Risk of Pharmacotherapy · 2022
  49. Genetic Risk Factors for Adverse Drug ReactionsSafety and Risk of Pharmacotherapy · 2022
  50. Safety of Therapy with Tocilizumab and Other Interleukin InhibitorsSafety and Risk of Pharmacotherapy · 2022